No Data
No Data
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
Travere Therapeutics to Report Third Quarter 2024 Financial Results
Wells Fargo Upgrades Travere Therapeutic(TVTX.US) to Buy Rating, Announces Target Price $27
Wells Fargo Upgrades Travere Therapeutics to Overweight From Equalweight, Adjusts Price Target to $27 From $9
12 Health Care Stocks Moving In Thursday's After-Market Session
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday